Worries About 180-Day Exclusivity Reforms Persist As User Fee Bill Advances

 
• By Derrick Gingery
  
FDA generic legislation
Generic advocates worry FDA's model legislation might render the 180-day exclusivity incentive almost irrelevant. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Generics

More from Biosimilars & Generics